bluebird bio (BLUE) Misses Q2 EPS by 39c

bluebird bio (NASDAQ: BLUE) reported Q2 EPS of ($3.58), $0.39 worse than the analyst estimate of ($3.19). Revenue for the quarter came in at $7.47 million versus the consensus estimate of $19.68 million.

For earnings history and earnings-related data on bluebird bio (BLUE) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22